What the research found

Researchers analysed PET-CT imaging from over 100,000 people and identified roughly 9% with detectable brown fat activity. When they matched brown fat–positive individuals with similar controls (accounting for age, sex, and BMI), those with active brown fat showed substantially lower odds of metabolic and mental health conditions: type 2 diabetes, cardiovascular disease, depression, and anxiety all appeared less common in this group. Blood work supported the pattern—better glucose control, lipid profiles, and HDL levels accompanied brown fat activity.

The study then screened 125 medications to understand what influences brown fat presence. Beta-blockers and SSRIs showed negative associations, while angiotensin receptor blockers (ARBs)—blood pressure drugs ending in "-sartan"—were positively linked to brown fat, with losartan showing a 36% higher odds of detection. The mechanism appears separate from blood pressure control: losartan breaks down into a metabolite that activates PPAR-γ, a regulator of fat cell function, which then upregulates UCP1 (the protein responsible for heat generation in brown fat). Mouse studies confirmed that losartan increased brown fat thermogenesis and whole-body energy expenditure.

Why it matters for you

If you're tracking metabolic markers—glucose, HbA1c, triglycerides, HDL—brown fat activity could be a meaningful upstream driver. Better brown fat function correlates with improved insulin sensitivity and lipid metabolism, both central to the longevity and metabolic optimisation most MyKine users pursue. This is especially relevant if you're using continuous glucose monitors or running periodic blood work to assess protocol effectiveness.

The medication angle is practical: if you're already on an ARB for hypertension, the data suggest an additional metabolic benefit beyond blood pressure control. Conversely, if you're on a beta-blocker or SSRI and noticing metabolic stagnation or unexpected weight gain, this finding provides one potential mechanism worth discussing with your doctor. The reversibility question—whether switching classes could restore brown fat activity—remains unanswered.

Cold exposure, exercise, and certain supplements have traditionally been linked to brown fat activation, though this paper doesn't detail those levers. For users already experimenting with cold plunges or high-intensity training, brown fat function represents one mechanistic benefit worth measuring if advanced imaging becomes accessible.

Caveats

• Observational design: The study shows association, not causation. People with brown fat differ in many ways beyond just brown fat status; unmeasured confounders (diet quality, physical activity intensity, sleep) could explain the health differences.
• Cross-sectional medication analysis: Medication associations are derived from snapshot imaging, not randomised trials. Losartan users may differ systematically from non-users in ways that affect both brown fat and disease risk.
• Animal-only efficacy data: Human energy expenditure effects of losartan on brown fat are inferred from mouse studies; direct human RCTs are absent.
• Small brown fat prevalence: Only 9% had detectable brown fat at baseline, limiting generalisability of findings to the broader population.
• Imaging threshold: PET-CT detection depends on metabolic activity at the time of scan—brown fat presence may be underestimated if scans occur in warm conditions or without cold stimulation.